Basit öğe kaydını göster

dc.contributor.authorPinar, Eymen
dc.contributor.authorKonte, Elif Kilic
dc.contributor.authorASLAN, ESMA
dc.contributor.authorHaslak, Fatih
dc.contributor.authorAdrovic, Amra
dc.contributor.authorŞAHİN, SEZGİN
dc.contributor.authorBARUT, KENAN
dc.contributor.authorKASAPÇOPUR, ÖZGÜR
dc.contributor.authorKilinc, Berivan
dc.contributor.authorÇEBİ, MEMNUNE NUR
dc.contributor.authorGunalp, Aybuke
dc.contributor.authorYILDIZ, Mehmet
dc.contributor.authorORAL CEBECİ, SİNEM
dc.date.accessioned2023-10-10T11:37:24Z
dc.date.available2023-10-10T11:37:24Z
dc.identifier.citationORAL CEBECİ S., YILDIZ M., Gunalp A., ÇEBİ M. N., Kilinc B., Pinar E., Konte E. K., ASLAN E., Haslak F., Adrovic A., et al., "The efficacy of a single-dose anakinra injection during disease attack in pediatric familial Mediterranean fever", RHEUMATOLOGY INTERNATIONAL, 2023
dc.identifier.issn0172-8172
dc.identifier.otherav_16bd559c-a7fd-4f04-a4d1-9b41192de220
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/189802
dc.identifier.urihttps://doi.org/10.1007/s00296-023-05351-0
dc.description.abstractThe aim of this retrospective study is to evaluate the efficacy of a single-dose anakinra during familial Mediterranean fever (FMF) attacks and its effect on the duration, severity, and frequency of attacks. The patients with FMF who had disease episode and received a single-dose anakinra during disease episode between December 2020 and May 2022 were included. Demographic characteristics, MEFV gene variants detected, concomitant medical conditions, demographics of recent and previous episodes, laboratory findings and length of hospital stay were recorded. A retrospective analysis of medical records revealed 79 attacks from 68 patients who met inclusion criteria. The patients had a median age of 13 (2.5-25) years. All patients reported that the average duration of their previous episodes lasted longer than 24 h. When the recovery time of attacks after subcutaneous anakinra application at the disease attack was examined, it was observed that 4 attacks (5.1%) ended in 10 min; 10 attacks (12.7%) in 10-30 min; 29 attacks (36.7%) in 30-60 min; 28 attacks (35.4%) in 1-4 h; 4 attacks (5.1%) in 24 h; and 4 attacks (5.1%) ended in more than 24 h. There was no patient who did not recover from their attack after a single dose of anakinra. Although the efficacy of a single-dose anakinra administration during FMF attacks in children needs to be confirmed by prospective studies, our results suggest that use of a single-dose anakinra during FMF attacks is effective in reduction of severity and duration of disease attacks.
dc.language.isoeng
dc.subjectROMATOLOJİ
dc.subjectSağlık Bilimleri
dc.subjectRomatoloji
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectİmmünoloji ve Romatoloji
dc.titleThe efficacy of a single-dose anakinra injection during disease attack in pediatric familial Mediterranean fever
dc.typeMakale
dc.relation.journalRHEUMATOLOGY INTERNATIONAL
dc.contributor.departmentİstanbul Üniversitesi-Cerrahpaşa , Cerrahpaşa Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü
dc.contributor.firstauthorID4313863


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster